Quality Regulatory Updates In Brief: ICH, EMA, MHRA and FDA
Executive Summary
ICH updates progress made on quality guidelines; EMA talks combination products; UK MHRA report sheds light on GMP deficiencies; MHRA official describes compliance escalation; FDA guides microbiology reviewers through Common Technical Document; FDA OKs reliance on non-USP compendia in applications.
You may also be interested in...
GMP Requirement Guidance For Combination Products Satisfies Industry
The guidance clarifies what constitutes a convenience kit, whether sponsors must submit GMP information in marketing applications and the applicability of combination product regulations to cross-labeled combination products.
Drug Makers Urged To Collect Own Excipient Metals Data To Comply With ICH Q3D
While leveraging published data may help pharmaceutical manufacturers understand the general risks of using excipients with known elemental impurities, it is less helpful in understanding specific risks.
ICH Sets Three-Year Goal To Harmonize Criteria For Biowaivers
ICH outlines an ambitious work plan to harmonize the disparate requirements for biowaivers among regulators worldwide; New concept paper and business plan highlight areas of disagreement.